Last updated: June 14, 2026
Litigation summary and analysis: Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc. (1:15-cv-00698)
Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc., No. 1:15-cv-00698 (filed 2015) is a Hatch-Waxman patent infringement dispute tied to a TWi generic launch attempt that Par treated as precluded by one or more Orange Book-listed patents. The case posture and litigation mechanics track a Paragraph IV strategy by the ANDA filer, with Par asserting infringement and seeking injunctive relief. The docket in this matter is not fully specified in the provided information, so no definitive claim chart, asserted patent numbers, counsel positions, trial dates, or settlement terms can be stated from the record here.
What patents protect the Par drug at issue in 1:15-cv-00698?
Answer (required elements not provided): The asserted patents, their publication/application numbers, and whether they include composition-of-matter, formulation, method-of-use, or manufacturing/process claims are not identifiable from the information supplied.
Which Orange Book patents were asserted?
Were formulation or method-of-use claims included?
Which jurisdiction and court handled the claims?
- Not provided beyond docket number format.
What is the litigation timeline for Par v. TWi Pharmaceuticals, 1:15-cv-00698?
Answer (required elements not provided): Key dates including complaint filing date confirmations, answer/submission dates, Markman scheduling, claim construction outcomes, dispositive motion rulings, and any final judgment or dismissal are not specified in the supplied input.
Procedural milestones to anchor exclusivity and entry risk
- Complaint filing: 2015 (year inferred from docket number context, exact date not provided).
- Claim construction, summary judgment, trial, and final disposition: not provided.
How does Paragraph IV certification drive the dispute in 1:15-cv-00698?
Answer (required elements not provided): The specific ANDA and the Paragraph IV certification trigger (certification date, patent numbers referenced in the notice, and the statutory basis for immediate litigation) are not stated in the provided information.
Was the case filed under 35 U.S.C. § 271(e)(2)?
- Expected for Hatch-Waxman, but not provable from the input.
Did Par seek a 30-month stay or other remedies?
What did the court decide in Par v. TWi Pharmaceuticals, 1:15-cv-00698?
Answer (required elements not provided): The dispositive outcome, including whether the court granted/denied injunctive relief, found infringement or invalidity, or whether the case ended via settlement/dismissal with a consent judgment, is not specified.
Infringement versus invalidity split?
Any claim construction affecting scope?
Final judgment date and form (injunction, dismissal, consent judgment)?
What settlement terms or consent judgment affected generic entry after 1:15-cv-00698?
Answer (required elements not provided): Settlement agreement terms, including “carve-outs” tied to dosing strengths, labeling limitations, launch timing, and any licensing component, are not included in the provided information.
Did the settlement include an authorization-to-launch after a date?
Did the settlement impose product- or process-design constraints?
Was there a damages component or covenant-not-to-sue?
How strong is Par’s patent estate in this litigation: what is the litigation-strength view?
Answer (required elements not provided): Without the asserted patent numbers and any claim construction or merits rulings, strength cannot be analyzed in an evidence-based way.
Typical factors to evaluate (not available here)
- Claim breadth and differences between branded and proposed generic.
- Prior art landscape and obviousness/enablement posture.
- Local infringement findings if a preliminary injunction or summary judgment occurred.
- Remaining life of asserted patents at the time of litigation.
What generic entry risks exist for TWi’s product after 1:15-cv-00698?
Answer (required elements not provided): The product and strength at issue are not identified, and no end-state (final judgment or settlement timing) is given.
Launch timing signals
FDA and label status linkage
Potential design-around pathways
How does 1:15-cv-00698 affect other generics or competitors?
Answer (required elements not provided): Without details on the patented claims, the marketed branded product, and the litigation outcome, downstream impact on other ANDA applicants cannot be deduced.
Any “most favored” rivals?
Does the case create collateral estoppel or licensing precedent?
What is the Orange Book status of the patents asserted in 1:15-cv-00698?
Answer (required elements not provided): Orange Book listings, registration numbers, expiration dates, and exclusivity expirations tied to the asserted patents are not included.
Patent expiration timeline
Exclusivity interaction (180-day exclusivity, pediatric, 5-year/3-year exclusivity)
Key Takeaways
- The docket identifies a Hatch-Waxman patent infringement action between Par and TWi under No. 1:15-cv-00698, consistent with a Paragraph IV-type generic challenge workflow.
- The specific asserted patents, their claim types, the procedural milestones, and the final outcome are not provided in the input, preventing a fact-grounded infringement/invalidity and settlement analysis.
- No Orange Book status, expiration timeline, or entry risk calendar can be stated from the information available here.
FAQs
-
What was the asserted patent list in Par Pharmaceutical v. TWi Pharmaceuticals (1:15-cv-00698)?
Not provided.
-
Did the court grant an injunction in 1:15-cv-00698 or end the case via settlement?
Not provided.
-
Was a 30-month stay triggered and did it delay launch for TWi?
Not provided.
-
Which ANDA product (drug name, strength, dosage form) is the subject of 1:15-cv-00698?
Not provided.
-
What is the Orange Book expiration date for the patents at issue in 1:15-cv-00698?
Not provided.
References
- No citable sources were provided in the prompt, and no docket, court opinion, or Orange Book listing details were included that can be referenced to support a litigation-specific summary.
